Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B

En-Qiang Chen¹,², Shu Feng³, Meng-Lan Wang¹,², Ling-Bo Liang¹,², Ling-Yun Zhou¹,², Ling-Yao Du¹,², Li-Bo Yan¹,², Chuan-Min Tao³ & Hong Tang¹,²

Recently, hepatitis B core-related antigen (HBcrAg) has been suggested as an additional marker of hepatitis B virus (HBV) infection. This study aimed to investigate whether serum quantitative HBcrAg (qHBcrAg) was a satisfactory surrogate marker of intrahepatic covalently closed circular DNA (cccDNA). A total of 139 patients with liver biopsy were enrolled, consisting of 59 patients in immune tolerance (IT) phase, 52 patients in immune clearance (IC) phase, 18 patients in low-replication (LR) phase, and 10 patients in reactivation phase. All patients in IC phase have received entecavir (ETV) therapy, and 32 of them undergone a second liver biopsy at 24 months. Among those patients, qHBcrAg was strongly correlated with intrahepatic cccDNA, which is superior to that of qHBsAg and HBV DNA. And similar findings were also observed in patients in IT, IC, LR and reactivation phases. Among the 32 ETV-treated patients with a second liver biopsy in IC phase, the decline of intrahepatic cccDNA was accompanied by changes in both qHBcrAg and qHBsAg. However, as compared to qHBsAg, the change of qHBcrAg was more strongly associated with intrahepatic cccDNA decline. In summary, serum qHBcrAg should be a satisfactory surrogate of intrahepatic HBV cccDNA in CHB patients.

Chronic hepatitis B (CHB) is a potentially life-threatening liver disease caused by hepatitis B virus (HBV) chronic infection. It remains a major global health issue affecting approximately 250 million people worldwide, especially in Asian countries¹. For a long time, controlling the intrahepatic HBV covalent closed circular DNA (cccDNA) level or its transcriptional activity is critical for achieving the goals of antiviral therapy to prevent the occurrence of decompensated cirrhosis and hepatocellular carcinoma²,³. So monitoring the dynamic changes of intrahepatic HBV cccDNA would be an accurate approach to evaluate the efficacy of current antiviral therapy ⁴,⁵. As we know, liver biopsy is an invasive procedure, with pain and major complications occurring in 40% and 0.5% of patients, respectively⁶. In real-life clinical practice, routine liver biopsy has not been well accepted by patients, and few of them could undergo dynamic liver biopsy examinations. And this embarrassment of liver biopsy has brought great difficulties to the evaluation of intrahepatic HBV cccDNA levels in CHB patients. Thus, searching for surrogate indicators of intrahepatic HBV cccDNA has always been a research hot spot in CHB studies. Though sustained serum HBV DNA suppression and HBeAg seroconversion are reported to be associated with disease remission⁷, their efficiency in reflecting changes of intrahepatic cccDNA is poor. In recent years, quantitative HBsAg (qHBsAg) has been proven to have a better correlation with intrahepatic cccDNA than either HBV DNA or HBeAg. Besides, a new enzyme immunoassay that detects hepatitis B core-related antigen (HBcrAg) also has been reported to reflect intrahepatic cccDNA recently⁸,⁹. According to reports in the literature, HBcrAg consists of HBcAg, HBeAg, and p22cr, which is a precore protein from amino acid −28 to at least amino acid −1.
acid 150, by coding the precore/core region\(^9\). However, this new serum indicator “HBcrAg” is still not widely known by clinician around the world, because there is not enough data available at present.

China is a country with the largest HBV infections in the world, and its epidemiological characteristics of CHB are different from that in other regions, especially in the United States and Europe. In present study, we will firstly investigate the distribution of serum qHBcrAg in real-life Chinese patients, assess the correlation of serum qHBcrAg with intrahepatic cccDNA, and evaluate whether serum qHBcrAg has superiority than serum qHBsAg in reflecting intrahepatic cccDNA.

### Methods

**Patients.** This was a retrospective cohort study consisting of CHB patients who underwent percutaneous liver biopsy at the West China Hospital between January 2009 and December 2013. Patients were excluded if they had co-infections (HCV and HIV) or other concomitant liver diseases such as alcoholic liver disease, autoimmune liver disease, and hepatocellular carcinoma. Patients without qualified serum (enough volume and qualified storage conditions) and liver tissue samples (no obvious degradation of DNA) for qHBcrAg and intrahepatic HBV cccDNA analysis were also excluded in this study.

A total of 139 eligible patients were included and classified into different phases of CHB, consisting of 59 patients in immune tolerance (IT) phase, 52 patients in immune clearance (IC) phase, 18 patients in low-replication (LR) phase, and 10 patients in reactivation phase. The criteria were based on the 2015 Asian-Pacific Association for the Study of the Liver clinical practice guidelines on the management of hepatitis B\(^10\). All patients in IC phase have received entecavir (ETV) therapy, and 32 of them undergone a second liver biopsy at 24 months after antiviral therapy. This retrospective study conformed to the Ethical Guidelines of the 1975 Declaration of Helsinki. Approval of this study was also obtained from the Ethics Committee of West China Hospital of Sichuan University, and verbal informed consent was obtained from each patient in this study.

**General laboratory evaluation.** Serum ALT levels were assessed according to standard procedures (Olympus AU5400, Olympus Corporation, Tokyo, Japan), and the upper limit of normal (ULN) ALT was defined as 50IU/L for men and 38IU/L for women. Serum HBsAg concentration was quantitatively assessed using Elecsys® HBsAg II Quant Assay (Roche Diagnostics, Penzberg, Germany), with a dynamic range of 20 to 52,000 IU/mL. If qHBsAg levels >52,000 IU/mL, samples were retested with a stepwise dilution of 1:4000. Serum hepatitis B e antigen (HBeAg) was determined by the electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, USA). Serum concentrations of HBV-DNA were determined using Cobas Taqman assay kit (Roche Diagnostics, Branchburg, NJ), with a lower limit of detection of 20 IU/mL. HBV genotypes were determined by direct S-gene sequencing.

**Quantitative intrahepatic HBV cccDNA evaluation.** Besides the role of an internal reference, \(\beta\)-actin could also act as an effective tools to distinguish qualified tissues from unqualified ones. The positive \(\beta\)-actin amplification is generally believable when positive signal is acquired within 30 cycles of PCR qualification. \(\beta\)-actin could also act as an effective tools to distinguish qualified tissues from unqualified ones. The positive signal of \(\beta\)-actin amplification was acquired within 25 cycles in all the samples. In other words, these liver samples were all validated tissues without obvious DNA degradation and could be used for further analysis.

Intrahepatic HBV cccDNA levels were measured with the real-time PCR method\(^11\). The total HBV DNA was extracted from paraffin embedded liver tissue using QIAamp DNA FFPE tissue assay kit (Qiagen, Hilden, Germany). After extraction, the products were incubated with plasmid-safe ATP-dependent (PSAD) DNase (Épicentre Technologies Corp., Chicago, USA) which selectively remove linear dsDNA, linear and close-circular ssDNA, to acquire purified cccDNA. Then a rolling circle amplification (RCA) with four pairs of primers (Table 1) were conducted to increase the amplification efficiency. With such pre-treatment, the sequential RT-PCR could detected an extremely low intrahepatic cccDNA.

The cccDNA-selective primers and a probe targeting the gap region between the viral genome direct repeat regions (DR1 and DR2) were used for HBV cccDNA specifically amplification and quantification (Table 1). While the cellular DNA was quantified by determining the copy number of the cellular \(\beta\)-actin house keeping gene, and primers and probe for \(\beta\)-actin amplification were also listed in Table 1. Additionally, ten-fold serial dilutions \((10^{-6}–10^0\text{ copies/mL})\) of a plasmid containing the entire wild-type HBV genome were used to establish standard curves for the quantitation of HBV cccDNA, and this plasmid was constructed and stored in the laboratory of our department.

In the process of detection, each sample was run in duplicate on the same plate. Liver biopsy tissues from HBV-uninfected patients were used as negative controls. The amount of HBV cccDNA was expressed as the number of copies per cell, with the estimation of 6.667 pg of DNA/cell.

**Quantitative serum HBcrAg evaluation.** The quantification of HBcrAg was performed using fully automated Lumipulse chemiluminescence enzyme immunoassay (CLEIA) analyser (Fujirebio Inc., Tokyo, Japan), as described previously. Briefly, serum was incubated with pretreatment containing sodium dodecyl sulphate and then incubated with monoclonal antibodies against denatured HBcAg and HBeAg. After washing and incubated with secondary antibodies, the concentrations of HBcrAg were determined by relative chemiluminescence intensity and compared with standard curve. Because the general analytic measurement range of this assay was between 1,000 U/mL (3 log10 U/mL) and 10,000,000 U/mL (7 log10 U/mL), serial dilutions of the serum sample is needed when serum qHBcrAg level above the detection limit of the assay.

**Statistical analyses.** Data were expressed as mean and SD for continuous variables and as counts and percentages for categorical variables. The differences between continuous variables were analyzed using the Student's
t test or Mann–Whitney test, as appropriate; and the comparison of continuous variables before and after antiviral therapy was analyzed using paired samples t test, considering a $P$ value less than 0.05 as statistically significant.

The correlation between two continuous variables was analyzed using Spearman’s bivariate correlation, and the correlation is significant at the 0.01 level (2-tailed). All statistical analyses were done with SPSS version 18.0 (SPSS, Chicago, IL), and all figures were drawn using GraphPad Prism 6 (GraphPad Software Inc., California, USA).

**Results**

**Patient characteristics.** Among the 139 eligible patients, there were more males (69.06%) than females, HBeAg-positive patients (79.86%) than HBeAg-negative patients, and HBV Genotype B (63.31%) than C. The mean levels of intrahepatic HBV cccDNA was $7.33 \pm 1.03$ log10 copies/10$^6$ cell; and mean levels of serum HBV DNA and HBsAg was $6.99 \pm 1.85$ log10 IU/mL and $4.15 \pm 0.86$ log10 IU/mL, respectively. The detailed characteristics of patients in total and in different phases of CHB were presented in Table 2.

**Serum HBcrAg distribution in CHB patients.** Among those 139 CHB patients, the serum qHBcrAg levels varied significantly and were widely distributed among different phases of HBV infection. As shown in Fig. 1, the level of qHBcrAg was ranged from 2.30 to 12.80 log10 U/mL, with a mean level of $9.23 \pm 2.86$ log10 U/mL. And the mean levels of qHBcrAg were $10.40 \pm 1.54$ log10 U/mL for patients in IT phase (median 10.7 log10 U/mL, range 6.2–12.5 log10 U/mL), $10.49 \pm 1.66$ log10 U/mL for patients in IC phase (median 10.9 log10 U/mL, range 6.2–12.5 log10 U/mL), $4.23 \pm 1.13$ log10 U/mL for patients in LR phase (median 4.15 log10 U/mL, range 2.3–6.4 log10 U/mL).
log_{10} U/mL), and 4.69 ± 0.93 log_{10} U/mL for patients in reactivation phase (median 4.90 log_{10} U/mL, range 3.2–6.5 log_{10} U/mL). There was no significant difference of qHBcrAg distribution between IT phase and IC phase ($P = 0.755$), LR phase and reactivation phase ($P = 0.439$), but significant difference was observed between IT and IC phases ($P = 0.001$).

**Figure 1.** The distribution of serum qHBcrAg in different phases of CHB.

**Figure 2.** The correlation of serum qHBcrAg with age (A), and distribution of serum qHBcrAg distinguished by gender (B), HBeAg status (C) and HBV genotype (D).
phase and LR phase ($P < 0.001$), IT phase and reactivation phase ($P < 0.001$), IC phase and LR phase ($P < 0.001$), IC phase and reactivation phase ($P < 0.001$).

Among those 139 patients, the distribution of serum qHBcrAg was statistically negatively correlated with age ($r = -0.505$, $P < 0.001$) (Fig. 2A), but not statistically different between males and females ($9.30 \pm 2.86 \log_{10} \text{U/mL}$ vs. $9.06 \pm 2.88 \log_{10} \text{U/mL}$, $P = 0.645$) (Fig. 2B). The serum level of qHBcrAg was significantly higher in HBeAg-positive patients than in HBeAg-negative patients ($10.45 \pm 1.59 \log_{10} \text{U/mL}$ vs. $4.39 \pm 1.07 \log_{10} \text{U/mL}$, $P < 0.001$) (Fig. 2C), but similar between genotype B and C HBV infected patients ($9.51 \pm 2.58 \log_{10} \text{U/mL}$ vs. $8.75 \pm 3.26 \log_{10} \text{U/mL}$, $P = 0.132$) (Fig. 2D).

Correlations of qHBcrAg with intrahepatic cccDNA and other clinical parameters. Among those 139 CHB patients, the serum qHBcrAg level was positively associated with intrahepatic cccDNA levels ($r = 0.929$, $P < 0.001$). The correlation of serum qHBcrAg level and intrahepatic cccDNA level was also statistically significant in all phases ($r = 0.852$, $P < 0.001$ for IT phase; $r = 0.790$, $P < 0.001$ for IC phase; $r = 0.730$, $P < 0.001$ for LR phase; and $r = 0.909$, $P < 0.001$ for reactivation phase) (Fig. 3A). Additionally, the serum level of qHBcrAg was also positively associated with serum HBV DNA ($r = 0.864$, $P < 0.001$) and qHBsAg ($r = 0.797$, $P < 0.001$), respectively (Fig. 4A and B). However, no significant correlation was observed between the qHBcrAg level and ALT level (Fig. 4C).

Among those 139 CHB patients, serum qHBsAg ($r = 0.742$, $P < 0.001$) and HBV DNA ($r = 0.854$, $P < 0.001$) levels were also positively associated with intrahepatic cccDNA level. However, their correlations were relatively weaker than that of qHBcrAg ($r = 0.929$, $P < 0.001$). Among patients in different phases, the correlations of qHBsAg with intrahepatic cccDNA were significant in the IT ($r = 0.811$, $P < 0.001$) and IC ($r = 0.652$, $P < 0.001$) phases, but not in the LR ($r = 0.249$, $P = 0.318$) and reactivation ($r = 0.423$, $P = 0.224$) phases (Fig. 3B). Similar
correlations were also observed between serum HBV DNA and intrahepatic cccDNA in the IT \( (r = 0.651, P < 0.001) \), IC \( (r = 0.431, P = 0.001) \), LR \( (r = 0.033, P = 0.897) \) and reactivation \( (r = 0.631, P = 0.050) \) phases (Fig. 3C). These findings indicated that serum qHBcrAg level was superior to either qHBsAg and HBV DNA in reflecting the intrahepatic cccDNA level in all phases of CHB.

**Dynamic changes of qHBcrAg and intrahepatic cccDNA levels during treatments.** The detailed information of ETV-treated patients with dynamic liver biopsy in the IC phase were presented in Table 3. During the 24 months of ETV treatment, the reductions of serum qHBcrAg and qHBsAg were accompanied by changes in intrahepatic cccDNA. As shown in Fig. 5, the mean levels of qHBcrAg were decreased from 10.35 ± 1.73 \( \log_{10} \) IU/mL to 6.58 ± 1.39 \( \log_{10} \) IU/mL, with a mean reduction of 3.77 ± 1.38 \( \log_{10} \) IU/mL; the mean levels of qHBsAg were decreased from 4.34 ± 0.73 \( \log_{10} \) IU/mL to 3.16 ± 0.59 \( \log_{10} \) IU/mL, with a mean reduction of 1.19 ± 0.88 \( \log_{10} \) IU/mL; and the mean levels of intrahepatic cccDNA were also decreased from 7.98 ± 1.30 \( \log_{10} \) copies/10⁶ cell to 6.64 ± 1.30 \( \log_{10} \) copies/10⁶ cell, with a mean reduction of 1.34 ± 0.63 \( \log_{10} \) copies/10⁶ cell.

Among these 32 ETV-treated patients in the IC phase, either before or after 24-month antiviral therapy, the correlation of qHBcrAg with intrahepatic cccDNA was higher than that of qHBsAg with intrahepatic cccDNA \( (r = 0.830 \text{ vs. } r = 0.684 \text{ before treatment}; r = 0.578 \text{ vs. } r = 0.536 \text{ after treatment}) \). Importantly, the dynamic changes of qHBcrAg \( (r = 0.665, P < 0.001) \) were more strongly associated with intrahepatic cccDNA-decline as compared to that of qHBsAg \( (r = 0.572, P = 0.001) \) (Fig. 5D and E).

**Discussion**

It is well known that the HBV genome exists in the nuclei of infected hepatocytes as a 3.2 kb double-stranded episomal DNA species called cccDNA. The cccDNA is a key component in the HBV life cycle, since it is the template for all viral genomic and subgenomic transcripts, and its level is well correlated with the proliferative potential of
HBV\(^{12}\). So monitoring the dynamic changes of intrahepatic cccDNA levels is important for accurately evaluating the effectiveness of current antiviral therapy and the risks of viral rebound resulting from discontinuation of nucleos(t)ide analogs (NAs) in CHB patients\(^4,13\). However, it is regrettable that the intrahepatic cccDNA is not routinely monitored in patients in real-life clinical practice due to the inconvenience of percutaneous liver biopsy and complexity of cccDNA examination. So serum markers reflecting the intrahepatic cccDNA level may be considered as a useful surrogate indicator.

Over the past decades, serum level of HBV DNA has been reported to correlate well with intrahepatic cccDNA levels in the natural course but not under nucleos(t)ide analogues therapy, because intrahepatic cccDNA decline did not parallel the rapid decrease of serum HBV DNA during a relative short duration of NAs therapy. Recently, HBcrAg has been suggested as an additional marker of HBV infection and reported to be correlated with intrahepatic cccDNA\(^7,14\). In this study, we firstly investigated the correlation of serum qHBcrAg with intrahepatic cccDNA in the different phases of CHB in Chinese mainland. It was to mention that the criteria of the four phases of CHB mentioned in this study were based on the 2015 APASL clinical practice guideline of CHB\(^10\), which had some difference with previous natural history definition of CHB\(^15\). As we expected, serum qHBcrAg not only has a significant positive correlation with intrahepatic cccDNA in nature course of CHB, but also this correlation is superior to that of serum qHBsAg with intrahepatic cccDNA. In addition, we also found that antiviral therapy could successfully reduce serum HBcrAg concentration, as well as serum HBV DNA and intrahepatic cccDNA levels, and this finding was supported by recent two similar studies\(^16,17\).

Importantly, the reductions of serum HBcrAg were also significantly positive correlated with the declines of intrahepatic cccDNA during treatment. Thus, it is easy to see that serum HBcrAg could be regarded as a satisfactory surrogate indicator of intrahepatic cccDNA and a better predictor of the long-term prognosis of CHB at present. As we known, the production of HBcrAg depends on the transcription of mRNA from cccDNA, so the reduction of HBcrAg is slower than that of serum HBV DNA in patients under nucleos(t)ide analogues therapy, and this may also explain why serum HBcrAg presents a significant positive correlation with intrahepatic cccDNA before and after ETV therapy.

In this study, the mean levels of serum qHBcrAg were higher than that reported in the literature\(^18\). This phenomenon may be related to the high percentage of positive HBeAg in this study, because HBeAg exists in serum at much higher concentrations than HBcAg and HBcrAg concentrations. In fact, we need to know that majority of patients with HBsAg loss/seroconversion still could detect intrahepatic HBV DNA and cccDNA. For example, Prof. Kumada H et al. recently have detected positive HBcrAg in 6 out of 13 HBsAg seroclearance patients.
patients, and the serum level of HBcAg is still correlated with intrahepatic cccDNA levels. So, according to current available evidences, serum qHBcAg should be more suitable than qHBsAg as an alternative indicator of intrahepatic cccDNA levels.

In this study, a negative correlation of qHBcAg with age is also observed. Thus, an accurate comparison of serum qHBcAg between groups should not ignore the possible interference of age and other related characteristics. Although our findings are exciting and believable, limitations are also inevitably existed. The low numbers of patients with unequal distribution in different phases of CHB should be the greatest weakness of this study. Thus, large sample (including both HBeAg positive and HBeAg-negative patients) and multi-center prospective studies are urgently needed to verify present findings. Additionally, the correlation of serum qHBcAg and intrahepatic cccDNA dynamic declines also should be verified in peginterferon alfa-treated patients.

In conclusion, serum qHBcAg is well correlated with intrahepatic cccDNA level in CHB, and qHBcAg is a good candidate to be a satisfactory surrogate marker. Thus the measurement of serum qHBcAg may be clinically useful for monitoring the viral status of intrahepatic HBV and predicting the long-term prognosis of CHB patients.

References
1. Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G. & Ott, J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* **386**, 1546–1555 (2015).
2. Tang, C. M., You, T. O. & Yu, J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. *World journal of gastroenterology* **20**, 6262–6278 (2014).
3. Nassal, M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. *Gut* **64**, 1972–1978 (2015).
4. Yang, H. C. & Kao, J. H. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. *Emerging microbes & infections* **3**, e64 (2014).
5. Zheng, Q. et al. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss. *Journal of viral hepatitis* **21**, 969–916 (2014).
6. Thampanitchawong, P. & Piratvisuth, T. Liver biopsy: complications and risk factors. *World journal of gastroenterology* **5**, 301–304 (1999).
7. Suzuki, F., Miyakoshi, H., Kobayashi, M. & Kumada, H. Correlation between serum hepatitis B virus core-related antigen and intrahepatically covalently closed circular DNA in chronic hepatitis B patients. *J Med Virol* **81**, 27–33 (2009).
8. Matsuzaki, T. et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. *J Gastroenterol Hepatol* **28**, 1217–1222 (2013).
9. Kimura, T. et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* **40**, 439–445 (2002).
10. Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* **10**, 1–98 (2016).
11. Zhong, Y. et al. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin embedded liver tissue using rolling circle amplification in combination with real-time PCR. *Clin Chim Acta* **412**, 1905–1911 (2011).
12. Tang, H., Banks, K. E., Anderson, A. L. & McLachlan, A. Hepatitis B virus transcription and replication. *Drug news & perspectives* **14**, 325–334 (2001).
13. Shi, M., Sun, W. L., Hua, Y. Y., Han, B. & Shi, L. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B. *PloS one* **10**, e0117741 (2015).
14. Maasoumy, B. et al. Hepatitis B core-related antigen (HBcAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. *Clin Microbiol Infect* **21**, 606 e601–610 (2015).
15. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* **57**, 167–185 (2012).
16. Tanaka, E., Matsumoto, A., Yoshizawa, K. & Maki, N. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. *Interwirology* **51** Suppl 1, 3–6 (2008).
17. van Campenhout, M. J. et al. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. *Clin Microbiol Infect* **22**, 571.e5–9 (2016).
18. Wong, D. K. et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. *J Clin Microbiol* **45**, 3942–3947 (2007).

Acknowledgements
This work was supported by grants from Science and Technology Support Program of Sichuan Province, China (2015SZ0049 and 2016SZ0042), and the National Twelve-Five Project of China (2012ZX10002007-001-003). We appreciate the assistance from Dr. Dong-Mei Zhang, Min He and Cong Liu, West China Hospital of Sichuan Hospital in collection and separation of blood samples.

Author Contributions
H.T. and E.Q.C. designed the study. E.Q.C. collected, analyzed the data with H.T., S.F., M.L.W., L.B.L., L.Y.Z., L.Y.D., L.B.Y., C.M.T., H.T. gave much advice and directions in both study design and preparing of the manuscript. All the authors have read and approved the final submitted version.

Additional Information
Competing Interests: The authors declare no competing financial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)}

© The Author(s) 2017